At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 359 enrolled
Drug / intervention
Oxycodone/Naloxonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week, Open Label, Multi-center, Prospective, Single-arm, Non-interventional Phase IV Study to Evaluate the Efficacy of Targin for the Treatment of Korean Patients With Cancer Pain Under Conditions of Daily Practice
In Brief
A Phase 4 clinical trial evaluating Oxycodone/Naloxone for Cancer. Completed, enrolled 359 participants across 1 site.
Detailed Summary
The aim of the study is to evaluate the efficacy of TARGIN administration as an analgesic to Korean patients treated with opioid analgesics for moderate-to-severe cancer pain under conditions of daily practice.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedNov 2012
Primary CompletionOct 2013
Study CompletionApr 2014
TodayJul 2026
First PostedNov 1, 2012
Enrollment StartJul 1, 2012
Primary CompletionOct 1, 2013
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.7 years ago
Interventions
Oxycodone/Naloxonedrug
Twice daily